{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T09:07:15Z","timestamp":1792487235931,"version":"4.5.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HC21C0028"],"award-info":[{"award-number":["HC21C0028"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","cghjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.cgh.2023.12.022","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T17:54:33Z","timestamp":1704390873000},"page":"981-993.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Reduction of Upper Gastrointestinal Bleeding Risk With Proton Pump Inhibitor Therapy in Asian Patients With Atrial Fibrillation Receiving Direct Oral Anticoagulant: A Nationwide Population-based Cohort Study"],"prefix":"10.1016","volume":"22","author":[{"given":"So-Ryoung","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo-Jeong","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0411-6372","authenticated-orcid":false,"given":"Eue-Keun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Hyun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Do","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seil","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2023.12.022_bib1","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ijcard.2017.02.039","article-title":"Trends in the incidence and prevalence of atrial fibrillation and estimated thromboembolic risk using the CHA(2)DS(2)-VASc score in the entire Korean population","volume":"236","author":"Lee","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cgh.2023.12.022_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0189495","article-title":"Temporal trends of antithrombotic therapy for stroke prevention in Korean patients with non-valvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants: a nationwide population-based study","volume":"12","author":"Lee","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.cgh.2023.12.022_bib3","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.119.005894","article-title":"Effectiveness and safety of direct oral anticoagulants in relation to temporal changes in their use","volume":"13","author":"Lee","year":"2020","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.cgh.2023.12.022_bib4","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1055\/s-0042-1750385","article-title":"Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: executive summary of a European and Asia-Pacific expert consensus paper","volume":"122","author":"Gorog","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.cgh.2023.12.022_bib5","doi-asserted-by":"crossref","DOI":"10.1177\/1756284821997352","article-title":"Burden of major gastrointestinal bleeding among oral anticoagulant-treated non-valvular atrial fibrillation patients","volume":"14","author":"Deitelzweig","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.cgh.2023.12.022_bib6","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2023.12.022_bib7","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2023.12.022_bib8","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2023.12.022_bib9","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2023.12.022_bib10","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2023.12.022_bib11","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/ajg.2012.444","article-title":"Guidelines for the diagnosis and management of gastroesophageal reflux disease","volume":"108","author":"Katz","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2023.12.022_bib12","doi-asserted-by":"crossref","first-page":"805","DOI":"10.7326\/M19-1795","article-title":"Management of nonvariceal upper gastrointestinal bleeding: guideline recommendations from the International Consensus Group","volume":"171","author":"Barkun","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cgh.2023.12.022_bib13","first-page":"728","article-title":"Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications","volume":"104","author":"Lanza","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2023.12.022_bib14","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","article-title":"COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease","volume":"363","author":"Bhatt","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2023.12.022_bib15","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1053\/j.gastro.2019.04.041","article-title":"COMPASS Investigators. Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban and\/or aspirin in a randomized, double-blind, placebo-controlled trial","volume":"157","author":"Moayyedi","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.12.022_bib16","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1001\/jama.2018.17242","article-title":"Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding","volume":"320","author":"Ray","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2023.12.022_bib17","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s10557-021-07170-6","article-title":"Proton pump inhibitor co-therapy in patients with atrial fibrillation treated with oral anticoagulants and a prior history of upper gastrointestinal tract bleeding","volume":"36","author":"Lee","year":"2022","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.cgh.2023.12.022_bib18","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1136\/heartjnl-2021-319332","article-title":"Non-vitamin K antagonist oral anticoagulants, proton pump inhibitors and gastrointestinal bleeds","volume":"108","author":"Komen","year":"2022","journal-title":"Heart"},{"key":"10.1016\/j.cgh.2023.12.022_bib19","first-page":"799","article-title":"Data resource profile: the National Health Information Database of the National Health Insurance Service in South Korea","volume":"46","author":"Cheol Seong","year":"2017","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.cgh.2023.12.022_bib20","doi-asserted-by":"crossref","first-page":"754","DOI":"10.4070\/kcj.2020.0171","article-title":"Cardiovascular research using the Korean National Health Information Database","volume":"50","author":"Choi","year":"2020","journal-title":"Korean Circ J"},{"key":"10.1016\/j.cgh.2023.12.022_bib21","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1161\/STROKEAHA.119.025536","article-title":"Effectiveness and safety of contemporary oral anticoagulants among Asians with nonvalvular atrial fibrillation","volume":"50","author":"Lee","year":"2019","journal-title":"Stroke"},{"key":"10.1016\/j.cgh.2023.12.022_bib22","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/pds.4783","article-title":"Assessment of ICD-10-CM code assignment validity for case finding of outpatient anticoagulant-related bleeding among Medicare beneficiaries","volume":"28","author":"Shehab","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.cgh.2023.12.022_bib23","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.amjmed.2022.04.001","article-title":"Outcomes and resource utilization in patients hospitalized with gastrointestinal bleeding complicated by types 1 and 2 myocardial infarction","volume":"135","author":"Nazir","year":"2022","journal-title":"Am J Med"},{"key":"10.1016\/j.cgh.2023.12.022_bib24","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.thromres.2019.07.021","article-title":"Accuracy of ICD-10 codes for identifying hospitalizations for acute anticoagulation therapy-related bleeding events","volume":"181","author":"Joos","year":"2019","journal-title":"Thromb Res"},{"key":"10.1016\/j.cgh.2023.12.022_bib25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s42444-019-0005-0","article-title":"Validation of diagnostic codes of major clinical outcomes in a National Health Insurance database","volume":"20","author":"Park","year":"2019","journal-title":"Int J Arrhythmia"},{"key":"10.1016\/j.cgh.2023.12.022_bib26","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1161\/STROKEAHA.120.030761","article-title":"Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and prior gastrointestinal bleeding","volume":"52","author":"Kwon","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.cgh.2023.12.022_bib27","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/sim.5984","article-title":"The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"key":"10.1016\/j.cgh.2023.12.022_bib28","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1093\/eurheartj\/ehr031","article-title":"An overview of the objectives of and the approaches to propensity score analyses","volume":"32","author":"Heinze","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cgh.2023.12.022_bib29","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"10.1016\/j.cgh.2023.12.022_bib30","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jacc.2016.10.060","article-title":"Comparison of propensity score methods and covariate adjustment: evaluation in 4 cardiovascular studies","volume":"69","author":"Elze","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cgh.2023.12.022_bib31","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"10.1016\/j.cgh.2023.12.022_bib32","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1136\/gutjnl-2015-310376","article-title":"Proton pump inhibitors affect the gut microbiome","volume":"65","author":"Imhann","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2023.12.022_bib33","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.gastro.2019.05.056","article-title":"COMPASS Investigators. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin","volume":"157","author":"Moayyedi","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.12.022_bib34","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2165\/11531320-000000000-00000","article-title":"Drug-drug interaction profiles of proton pump inhibitors","volume":"49","author":"Ogawa","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cgh.2023.12.022_bib35","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/j.1538-7836.2011.04579.x","article-title":"Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial: a rebuttal","volume":"10","author":"Patel","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.cgh.2023.12.022_bib36","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1055\/a-1369-5274","article-title":"Endoscopic diagnosis and management of nonvariceal upper gastrointestinal hemorrhage (NVUGIH): European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2021","volume":"53","author":"Gralnek","year":"2021","journal-title":"Endoscopy"},{"key":"10.1016\/j.cgh.2023.12.022_bib37","first-page":"30","article-title":"Risk factors and prevention of dabigatran-related gastrointestinal bleeding in patients with atrial fibrillation","volume":"34","author":"Nantsupawat","year":"2018","journal-title":"J\u00a0Arrhythm"},{"key":"10.1016\/j.cgh.2023.12.022_bib38","doi-asserted-by":"crossref","first-page":"57","DOI":"10.5009\/gnl19009","article-title":"Korean College of Helicobacter and Upper Gastrointestinal Research. The role of acid suppressants in the prevention of anticoagulant-related gastrointestinal bleeding: a systematic review and meta-analysis","volume":"14","author":"Bang","year":"2020","journal-title":"Gut Liver"},{"key":"10.1016\/j.cgh.2023.12.022_bib39","doi-asserted-by":"crossref","first-page":"4676","DOI":"10.1111\/bcp.15478","article-title":"Protective effect of proton-pump inhibitor against gastrointestinal bleeding in patients receiving oral anticoagulants: a systematic review and meta-analysis","volume":"88","author":"Ahn","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cgh.2023.12.022_bib40","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1161\/STROKEAHA.115.009947","article-title":"Non-vitamin K antagonist oral anticoagulants for stroke prevention in Asian patients with nonvalvular atrial fibrillation: meta-analysis","volume":"46","author":"Wang","year":"2015","journal-title":"Stroke"},{"key":"10.1016\/j.cgh.2023.12.022_bib41","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1136\/heartjnl-2017-312930","article-title":"Increasing trends in hospital care burden of atrial fibrillation in Korea, 2006 through 2015","volume":"104","author":"Kim","year":"2018","journal-title":"Heart"},{"key":"10.1016\/j.cgh.2023.12.022_bib42","first-page":"1485","article-title":"Temporal trends of emergency department visits of patients with atrial fibrillation: a nationwide population-based study","volume":"9","author":"Lee","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.cgh.2023.12.022_bib43","first-page":"37","article-title":"Pharmacogenetics of direct oral anticoagulants: a systematic review","volume":"11","author":"Raymond","year":"2021","journal-title":"J\u00a0Pers Med"},{"key":"10.1016\/j.cgh.2023.12.022_bib44","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s40256-023-00582-9","article-title":"Management of gastrointestinal bleeding and resumption of oral anticoagulant therapy in patients with atrial fibrillation: a multidisciplinary discussion","volume":"23","author":"Martin","year":"2023","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.cgh.2023.12.022_bib45","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.gie.2013.04.179","article-title":"Novel oral anticoagulants in gastroenterology practice","volume":"78","author":"Desai","year":"2013","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.cgh.2023.12.022_bib46","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.3748\/wjg.v23.i11.1954","article-title":"Gastrointestinal bleeding in patients on novel oral anticoagulants: risk, prevention and management","volume":"23","author":"Cheung","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cgh.2023.12.022_bib47","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1097\/MJT.0000000000000599","article-title":"The impact of proton pump inhibition on dabigatran levels in patients with atrial fibrillation","volume":"26","author":"Bolek","year":"2019","journal-title":"Am J Ther"},{"key":"10.1016\/j.cgh.2023.12.022_bib48","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1055\/s-0039-1695735","article-title":"Proton pump inhibitors and dabigatran therapy: impact on gastric bleeding and dabigatran plasma levels","volume":"45","author":"Bolek","year":"2019","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.cgh.2023.12.022_bib49","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.117.003998","article-title":"Gastrointestinal bleeding with edoxaban versus warfarin: results from the ENGAGE AF-TIMI 48 trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction)","volume":"11","author":"Aisenberg","year":"2018","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.cgh.2023.12.022_bib50","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1111\/j.1538-7836.2011.04378.x","article-title":"Bleeding risk in \u2018real world\u2019 patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort","volume":"9","author":"Olesen","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.cgh.2023.12.022_bib51","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/ehjqcco\/qcad019","article-title":"Impact of frailty on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a nationwide cohort study","volume":"10","author":"Grymonprez","year":"2024","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.cgh.2023.12.022_bib52","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.jacc.2013.11.013","volume":"63","author":"Goodman","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cgh.2023.12.022_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2019.10.013","article-title":"Gastrointestinal bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial","volume":"221","author":"Garcia","year":"2020","journal-title":"Am Heart J"},{"key":"10.1016\/j.cgh.2023.12.022_bib54","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/j.jacc.2015.09.024","article-title":"Gastrointestinal bleeding in patients with atrial fibrillation treated with rivaroxaban or warfarin: ROCKET AF trial","volume":"66","author":"Sherwood","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cgh.2023.12.022_bib55","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1111\/jth.15466","article-title":"Anticoagulant-associated gastrointestinal bleeding: framework for decisions about whether, when and how to resume anticoagulants","volume":"19","author":"Xu","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.cgh.2023.12.022_bib56","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.110.004747","article-title":"Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial","volume":"123","author":"Eikelboom","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.cgh.2023.12.022_bib57","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.thromres.2016.02.005","article-title":"Effectiveness and outcome of management strategies for dabigatran- or warfarin-related major bleeding events","volume":"140","author":"Majeed","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.cgh.2023.12.022_bib58","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1093\/eurheartj\/ehu083","article-title":"ROCKET AF Investigators. Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial","volume":"35","author":"Piccini","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cgh.2023.12.022_bib59","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.thromres.2019.01.020","article-title":"Resumption of anticoagulant therapy after anticoagulant-related gastrointestinal bleeding: a systematic review and meta-analysis","volume":"175","author":"Little","year":"2019","journal-title":"Thromb Res"},{"key":"10.1016\/j.cgh.2023.12.022_bib60","article-title":"ENGAGE AF-TIMI 48 Trial Investigators. Impact of spontaneous extracranial bleeding events on health state utility in patients with atrial fibrillation: results from the ENGAGE AF-TIMI 48 trial","volume":"6","author":"Wang","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.cgh.2023.12.022_bib61","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1161\/CIRCULATIONAHA.118.036710","article-title":"Idarucizumab for dabigatran reversal in the management of patients with gastrointestinal bleeding","volume":"139","author":"Van der Wall","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cgh.2023.12.022_bib62","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3324\/haematol.2017.182220","article-title":"A\u00a0three-year prospective study of the presentation and clinical outcomes of major bleeding episodes associated with oral anticoagulant use in the UK (ORANGE study)","volume":"103","author":"Green","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.cgh.2023.12.022_bib63","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.thromres.2021.10.022","article-title":"Risk factors and one-year mortality in patients with direct oral anticoagulant-associated gastrointestinal bleeding","volume":"208","author":"Verso","year":"2021","journal-title":"Thromb Res"},{"key":"10.1016\/j.cgh.2023.12.022_bib64","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1055\/s-0041-1739411","article-title":"2021 focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary","volume":"122","author":"Chao","year":"2022","journal-title":"Thromb Haemost"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356524000028?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356524000028?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T01:12:42Z","timestamp":1731114762000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356524000028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1542356524000028"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2023.12.022","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduction of Upper Gastrointestinal Bleeding Risk With Proton Pump Inhibitor Therapy in Asian Patients With Atrial Fibrillation Receiving Direct Oral Anticoagulant: A Nationwide Population-based Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2023.12.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the AGA Institute","name":"copyright","label":"Copyright"}]}}